Altimmune reported strong progress in its clinical programs for pemvidutide, positioning itself at a pivotal juncture with upcoming data readouts and regulatory meetings that could accelerate its growth in treating liver diseases.

• Anticipating Q4 disclosure of 48-week IMPACT trial data, building on positive 24-week results showcasing rapid efficacy in liver disease treatment.
• Secured in-person end of Phase II meeting with the FDA to discuss Phase III trial design, emphasizing an alignment with regulatory expectations.
• Completed enrollment ahead of schedule in the RECLAIM Phase II trial for alcohol use disorder, reflecting strong interest and operational efficiency.
• Expanded leadership team with key appointments to drive future clinical and commercial strategies.